Endohepatology-Based Reclassification of Treatment Indication in High-Risk Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective, Multicenter Observational Study
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease. Non-invasive testing is followed, when indicated, by a single-session endohepatology assessment including EUS-guided shear-wave elastography, portal pressure gradient measurement and liver biopsy. The primary outcome is treatment reclassification compared with the prospectively documented non-invasive assessment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age 18 years or older
• Written informed consent
• Suspected MASLD
• At least one predefined risk criterion
Locations
Other Locations
Germany
University Hospital Muenster
RECRUITING
Münster
Contact Information
Primary
Michael Prof. Dr. Praktiknjo, MD PhD
michael.praktiknjo@ukmuenster.de
0049 251 83 44826
Backup
Dominik Dr. van de Loo, MD
dominikjulian.vandeloo@ukmuenster.de
0049 251 83 44476
Time Frame
Start Date: 2026-10-05
Estimated Completion Date: 2030-04-01
Participants
Target number of participants: 500
Treatments
Low-risk group
Participants with low-risk and reliable non-invasive findings undergo non-invasive follow-up.
Endohepatology group
Participants with abnormal or unreliable non-invasive findings undergo endohepatology within 4 to 8 weeks.
Related Therapeutic Areas
Sponsors
Leads: University Hospital Muenster